CZTA Stock Overview
A clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Checkpoint Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.56 |
| 52 Week High | US$3.04 |
| 52 Week Low | US$1.29 |
| Beta | 1.3 |
| 11 Month Change | 23.37% |
| 3 Month Change | 9.64% |
| 1 Year Change | 37.78% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| CZTA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 21.6% | 1.5% | 0.4% |
| 1Y | 37.8% | -10.3% | 14.9% |
Return vs Industry: CZTA exceeded the German Biotechs industry which returned -10.3% over the past year.
Return vs Market: CZTA exceeded the German Market which returned 14.9% over the past year.
Price Volatility
| CZTA volatility | |
|---|---|
| CZTA Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CZTA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CZTA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 23 | James Oliviero | checkpointtx.com |
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Checkpoint Therapeutics, Inc. Fundamentals Summary
| CZTA fundamental statistics | |
|---|---|
| Market cap | €117.24m |
| Earnings (TTM) | -€39.22m |
| Revenue (TTM) | €72.03k |
1,714x
P/S Ratio-3.1x
P/E RatioIs CZTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CZTA income statement (TTM) | |
|---|---|
| Revenue | US$78.00k |
| Cost of Revenue | US$26.77m |
| Gross Profit | -US$26.69m |
| Other Expenses | US$15.77m |
| Earnings | -US$42.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -34,223.08% |
| Net Profit Margin | -54,444.87% |
| Debt/Equity Ratio | 0% |
How did CZTA perform over the long term?
See historical performance and comparison